

Botulinum Toxin Injection for Facial Wrinkles

REBECCA SMALL, MD, *University of California–San Francisco, San Francisco, California*

Botulinum toxin injection for treatment of facial wrinkles is the most frequently performed cosmetic procedure in the United States, and it is one of the most common entry procedures for clinicians seeking to incorporate aesthetic treatments into their practice. Treatment of frown lines and crow's feet, which are the cosmetic indications approved by the U.S. Food and Drug Administration, and horizontal forehead lines, offers predictable results, has few adverse effects, and is associated with high patient satisfaction. Wrinkles are formed by dermal atrophy and repetitive contraction of underlying facial musculature. Botulinum toxin is a potent neurotoxin that inhibits release of acetylcholine at the neuromuscular junction. Injection of small quantities of botulinum toxin into specific overactive muscles causes localized muscle relaxation that smooths the overlying skin and reduces wrinkles. Botulinum toxin effects take about two weeks to fully develop and last three to four months. Dynamic wrinkles, seen during muscle contraction, yield more dramatic results than static wrinkles, which are visible at rest. Botulinum toxin injection is contraindicated in persons with keloidal scarring, neuromuscular disorders (e.g., myasthenia gravis), allergies to constituents of botulinum toxin products, and body dysmorphic disorder. Minor bruising can occur with botulinum toxin injection. Temporary blepharoptosis and eyebrow ptosis are rare complications that are technique-dependent; incidence declines as injector skill improves. (*Am Fam Physician.* 2014;90(3):168-175. Copyright © 2014 American Academy of Family Physicians.)

CME This clinical content conforms to AAFP criteria for continuing medical education (CME). See CME Quiz Questions on page 145.

Author disclosure: No relevant financial affiliations.

► See related editorial on page 136.

► **Patient information:** A handout on this topic, written by the author of this article, is available at <http://www.aafp.org/afp/2014/0801/168-s1.html>.

Botulinum toxin injection for treatment of facial wrinkles is the most frequently performed cosmetic procedure in the United States,¹ and it is one of the most common entry procedures for clinicians seeking to incorporate aesthetic treatments into their practice.² Botulinum toxin injection, particularly in the upper one-third of the face, offers predictable results,³ has few adverse effects,⁴ and is associated with high patient satisfaction.⁵ This article reviews relevant facial anatomy, patient selection, complications, and injection technique for cosmetic botulinum toxin treatment with a focus on frown lines. It is, however, not intended as a replacement for a formal instructional course.

Mechanism of Action

Wrinkles are formed by dermal atrophy and repetitive contraction of underlying facial musculature. Injection of small quantities of botulinum toxin into specific overactive muscles causes localized muscle relaxation that smooths the overlying skin and reduces wrinkles.⁶

Botulinum toxin is a potent neurotoxin protein derived from the *Clostridium botulinum* bacterium. It exerts its effect at the neuromuscular junction by inhibiting the release of acetylcholine, which causes

temporary chemical denervation. At the cellular level, botulinum toxin functions by cleaving a docking protein (synaptosomal-associated protein of 25 kDa [SNAP-25]) on the internal surface of neuronal membranes, thereby inhibiting vesicle fusion and release of acetylcholine.⁷ Botulinum toxin effects in the targeted muscles diminish over time as SNAP-25 regenerates, and neuromuscular signaling and muscle contractility are restored.

Indications

Botulinum toxin has been used for more than 20 years to treat a variety of conditions including blepharospasm, strabismus, cervical dystonia, migraines, hyperhidrosis, and muscle spasticity. Botulinum toxin was first approved by the U.S. Food and Drug Administration (FDA) for cosmetic use in 2002 as Botox to treat glabellar complex muscles that form frown lines and in 2013 to treat lateral orbicularis oculi muscles that form crow's feet⁸; it is used off-label for all other cosmetic facial indications. It has become the treatment of choice for wrinkles occurring in the upper one-third of the face (i.e., frown lines, horizontal forehead lines, and crow's feet). It is also used in the lower two-thirds of the face, but this is more technically challenging and is an advanced application.⁹⁻¹⁴




Figure 1. Musculature of the face.

Reprinted with permission from Small R, Hoang D. A Practical Guide to Botulinum Toxin Procedures. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2012.

Anatomy

The muscles of facial expression are unique in that they have soft tissue attachments to skin through the superficial muscular aponeurotic system, unlike most muscles, which have bony attachments (Figure 1¹⁵). When facial muscles contract, the overlying skin also moves, forming dynamic wrinkles perpendicular to the direction of muscle contraction (Figure 2¹⁵).

Glabellar wrinkles, or frown lines, are vertical lines occurring between the medial aspects of the eyebrows. The muscles contributing to formation of frown lines are




Figure 2. Wrinkles of the face (associated muscle).

Reprinted with permission from Small R, Hoang D. A Practical Guide to Botulinum Toxin Procedures. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2012.

the glabellar complex depressor muscles, which include the corrugator supercilii, procerus, and depressor supercilii. Contraction of these muscles pulls the brows medially and inferiorly (Figure 3¹⁵).

Patient Selection

Patients with dynamic wrinkles demonstrate the most dramatic improvements from botulinum toxin injection and are ideal candidates for treatment (Figure 4¹⁵). Patients with static wrinkles that are visible at rest are also candidates (Figure 5¹⁵), but results are slower and patients may require two or three consecutive



Expression lines	Muscle	Action
Frown lines	Corrugator supercilii	Eyebrows drawn medially
	Procerus and depressor supercilii	Eyebrow depressors
Horizontal forehead lines	Frontalis	Eyebrow levator
Crow's feet	Lateral orbicularis oculi	Lateral eyebrow depressor
Eyebrow lift	Superior lateral orbicularis oculi	Superior lateral eyebrow depressor
Bunny lines	Nasalis	Nose drawn up and medially
Radial lip lines	Orbicularis oris	Lip puckering
Marionette lines and downturned smile	Depressor anguli oris	Corner of mouth depressor
Gummy smile and nasolabial fold	Levator labii superioris alaeque nasi	Central lip levator
Chin line and pebbly chin	Mentalis	Chin texture and lower lip levator

Key: orange = depressor muscles; purple = levator muscles; gray = sphincteric muscles.

Figure 3. Functional anatomy of the face.

Reprinted with permission from Small R, Hoang D. A Practical Guide to Botulinum Toxin Procedures. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2012.



Figure 4. Ideal candidate for botulinum toxin treatment demonstrating (A) dynamic frown lines with glabellar complex muscle contraction and (B) lack of static lines with glabellar muscles at rest.

Copyright © Rebecca Small, MD.

Reprinted from Small R, Hoang D. A Practical Guide to Botulinum Toxin Procedures. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2012.



Figure 5. (A) Dynamic frown lines with glabellar complex muscle contraction and (B) static lines with glabellar muscles at rest.

Copyright © Rebecca Small, MD.

Reprinted from Small R, Hoang D. A Practical Guide to Botulinum Toxin Procedures. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2012.

Table 1. Contraindications to Botulinum Toxin Injection

Body dysmorphic disorder
Dependency on facial expression for livelihood (e.g., actors, singers)
Dermatoses in the treatment area (e.g., psoriasis, eczema)
Gross motor weakness in the treatment area (e.g., Bell palsy)
Immunocompromised
Infection in the treatment area
Keloidal scarring
Neuromuscular disorder (e.g., amyotrophic lateral sclerosis, myasthenia gravis, Lambert-Eaton syndrome, myopathies)
Pregnancy or breastfeeding
Sensitivity or allergy to constituents of the botulinum toxin product (e.g., cow's milk protein allergy with abobotulinumtoxinA [Dysport])
Unrealistic expectations

Information from references 14, and 16 through 18.

botulinum toxin treatments for significant improvements.¹⁵ Deep static lines may not fully respond to botulinum toxin injection alone and may require combination treatment with dermal fillers or other cosmetic procedures to achieve optimal results. Setting realistic expectations at the time of consultation is important for patient satisfaction and success with botulinum toxin treatments. Contraindications to botulinum toxin injection include keloidal scarring, neuromuscular disorders (e.g., myasthenia gravis), allergy to constituents of botulinum toxin product, unrealistic expectations, and body dysmorphic disorder (Table 1).^{14,16-18}

Botulinum Toxin Products

The *C. botulinum* bacterium produces eight serotypes of botulinum toxin protein (A, B, C α , C β , D, E, F, and G). Botulinum toxin serotype A is the most potent and is used

for cosmetic treatments. Botulinum toxin serotype B is used for medical conditions such as dystonia. There are currently three botulinum toxin serotype A products approved by the FDA for cosmetic use to treat glabellar complex muscles that form frown lines: onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), and incobotulinumtoxinA (Xeomin), which are summarized in Table 2.^{19,20} All three serotype A products have a 150 kDa core botulinum toxin protein and differ in whether they have complexing proteins surrounding the core neurotoxin. OnabotulinumtoxinA and abobotulinumtoxinA have hemagglutinin complexing proteins,

whereas incobotulinumtoxinA is free from complexing proteins.^{19,21} Lack of complexing proteins may reduce antigenicity and hence antibody formation against botulinum toxin, but the clinical significance of complexing proteins has yet to be determined. Botulinum toxin products are not interchangeable because they vary in their formulation, dosing, and clinical response.

Aesthetic Consultation

Facial areas of concern are assessed by the physician and patient simultaneously using a handheld mirror during the consultation. Asymmetries such as uneven eyebrow height and eye aperture are identified. Areas are prioritized and treatment options discussed, including anticipated results and possible complications. Botulinum toxin is the only treatment for dynamic wrinkles currently approved by the FDA. Treatment options for static

Table 2. Botulinum Toxin Injectable Products

Trade name	Company	Toxin component	Other components	Dose for frown line treatment*	Cost
Botox	Allergan, Inc.	OnabotulinumtoxinA	Human albumin, sodium chloride	20 to 25 units	\$525 for 100-unit vial
Dysport	Medicis Pharmaceutical Corporation	AbobotulinumtoxinA	Human albumin, bovine protein, [†] lactose monohydrate	50 to 60 units [‡]	\$475 for 300-unit vial
Xeomin	Merz Pharmaceuticals	IncobotulinumtoxinA	Human albumin, sucrose	20 to 25 units [§]	\$425 for 100-unit vial

*—These starting doses are intended as general guidelines and may be adjusted at the time of treatment based on the patient's anatomy and glabellar complex muscle mass.

[†]—AbobotulinumtoxinA should not be used in patients with cow's milk protein allergy.

[‡]—OnabotulinumtoxinA to abobotulinumtoxinA strength of action ratio 1:2.5.

[§]—OnabotulinumtoxinA to incobotulinumtoxinA strength of action ratio 1:1.

Information from references 19 and 20.



Figure 6. Botulinum toxin injection into a contracted glabellar complex muscle.

Copyright © Rebecca Small, MD.

Reprinted from Small R, Hoang D. A Practical Guide to Botulinum Toxin Procedures. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2012.

wrinkles include resurfacing procedures (e.g., chemical peels, microdermabrasion, lasers), topical products (e.g., retinoids), and surgical procedures. Photographic documentation is recommended with any aesthetic procedure. Dynamic and static photographs of treatment areas are typically taken before treatment and two weeks after treatment, once clinical effects are evident.²²

Procedure Preparation

In preparation for botulinum toxin treatment, or any injectable procedure, bruising can be minimized by advising patients to discontinue aspirin and any medication or dietary supplement that has anticoagulant effects two weeks before treatment.^{17,23} Anesthesia is not typically necessary for botulinum toxin treatments.

Botulinum Toxin Injection

Botulinum toxin is supplied as a powder and is reconstituted at the time of treatment into a solution using sterile normal saline. Dilution volumes range from 1 to 4 mL per 100-unit vial. The botulinum toxin dose injected into glabellar complex muscles for the treatment of frown lines is based on the specific botulinum toxin product used and mass of the target muscles. *Table 2* lists starting doses used for treatment of frown lines with the three FDA-approved botulinum toxin products.^{19,20}

The targeted glabellar complex muscles can be identified by having the patient actively frown, and injections are placed into the contracted muscles (*Figure 6*¹⁵). Small volumes of botulinum toxin solution are injected, typically 1 mL or less, using a 30-gauge, 1-inch needle. There are five injection sites, one injection in the procerus muscle and two in each of the corrugator supercilii muscles.^{15,20,24} Botulinum toxin is commonly used to treat other lines in the upper one-third of the face, such as horizontal forehead lines with injection in the frontalis muscle, and crow's feet with injection in the lateral orbicularis oculi muscles.^{10,11,25} Localized burning or stinging sensation during injection is commonly reported and resolves within a few minutes.^{15,17}

Aftercare

Patients are advised to avoid lying supine following treatment for four hours. They are also advised to avoid massaging or applying heat to the treatment area, and to avoid activities that cause flushing (such as exercising heavily, consuming alcohol, and hot tub use) on the day of treatment.^{15,26} These aftercare practices are used to reduce potential spread of the toxin, however; they are not supported by randomized controlled trials.

Results and Follow-Up

Partial reduction in function of the targeted glabellar complex muscles is seen by the third day after botulinum toxin injection, with maximal reduction visible two weeks after injection.²⁷ *Figure 7* shows reduction of dynamic frown lines one month after treatment of the glabellar complex muscles with 20 units of onabotulinumtoxinA.¹⁵ Return of muscle function is gradual, typically three to four months after treatment. Subsequent treatment is advised when muscle contraction is visible in the treatment area before facial lines return to their pretreatment appearance.²⁸ After multiple treatments, botulinum toxin effects may be prolonged and, for some patients, treatment intervals can be extended beyond three to four months.²⁹

Complications

Complications with cosmetic botulinum toxin injections are uncommon and those that occur are usually mild and transient.³⁰ They can be categorized into injection reactions and undesired botulinum toxin effects (*Table 3*).³⁰⁻³²

INJECTION REACTIONS

Botulinum toxin injections are performed using small-gauge needles to minimize discomfort and bruising.



Figure 7. Dynamic frown lines with glabellar complex muscle contraction (A) before and (B) one month after onabotulinumtoxinA (Botox) treatment.

Copyright © Rebecca Small, MD.

Reprinted from Small R, Hoang D. *A Practical Guide to Botulinum Toxin Procedures*. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2012.



Figure 8. Right-sided blepharoptosis three weeks after botulinum toxin treatment of the glabellar complex for frown lines.

Copyright © Rebecca Small, MD.

Reprinted from Small R, Hoang D. *A Practical Guide to Botulinum Toxin Procedures*. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2012.

Mild erythema, edema, and tenderness at injection sites are expected and resolve within a day. Bruising is common and ranges from pinpoint needle insertion marks to quarter-sized ecchymoses that can take up to two weeks to resolve. Application of ice and pressure to a bruise can minimize enlargement.¹⁵ Headaches can occur with facial injections; most are mild and spontaneously resolve a few days after treatment.³³ There are reports of idiosyncratic severe headaches lasting two to four weeks.³⁴ Nonsteroidal anti-inflammatory drugs or opioids may be used to manage headaches based on severity. Infection is rare, but can occur with any procedure that breaches the skin barrier. Paresthesia or dysesthesia in the treatment area is rare, and may be caused by nerve trauma. Anxiety with injection procedures is common. Vasovagal episodes associated with severe anxiety can occur and it is advisable to have appropriate emergency protocols and medications available in the office when performing injection procedures.³⁵

UNDESIRE EFFECTS

Complications related to botulinum toxin effects occur less frequently than injection reactions, and are primarily caused by temporary denervation of adjacent muscles outside of the intended treatment area. These complications are technique-dependent; incidence declines as injector skill improves.^{30,31} Temporary blepharoptosis (upper eyelid droop) is uncommon (1% to 5%) but is distressing for patients.⁹ It is almost always unilateral, seen as a 2- to 3-mm lowering of the affected eyelid that is most marked at the end of the day with muscle fatigue (Figure 8¹⁵). Blepharoptosis is caused by deep migration of botulinum toxin through the orbital septum fascia to the levator palpebrae superioris, an upper eyelid levator muscle. Incidence of blepharoptosis is reduced by placing botulinum toxin injections at least 1 cm above the

Table 3. Complications with Botulinum Toxin Injection

Injection reactions

- Anxiety or vasovagal episode
- Ecchymosis
- Erythema, edema, and tenderness
- Headache
- Infection
- Pain
- Paresthesia or dysesthesia

Undesired botulinum toxin effects

- Allergic reaction
- Antibodies against botulinum toxin
- Blepharoptosis
- Distant spread from the injection site
- Eyebrow ptosis
- Facial asymmetry
- Medication interactions
- Undesired eyebrow shape or unsatisfactory result

Information from references 30 through 32.

Botulinum Toxin Injection

supraorbital ridge at the midpupillary line when treating the corrugator muscles.^{14,17} Blepharoptosis may be treated using ophthalmic solutions that have alpha-adrenergic effects, such as over-the-counter naphazoline 0.025%/pheniramine 0.3% or prescription apraclonidine 0.5% (Iopidine). Both medications cause contraction of Müller muscle, an adrenergic levator muscle of the upper eyelid, resulting in elevation of the upper eyelid. Apraclonidine is reserved for refractory cases and should be used with caution because it can exacerbate or unmask underlying glaucoma.³² Eyebrow ptosis and undesired eyebrow shape are usually related to unintended botulinum toxin effects in the frontalis muscle. Some of these complications can be corrected with botulinum toxin injection in muscles that antagonize the affected muscles; however, complications caused by involvement of adjacent muscles are temporary and will spontaneously resolve as botulinum toxin effects diminish. Facial asymmetry can result from uneven dosing of botulinum toxin. Consistent technique and careful attention to injection volumes at the time of treatment can reduce the incidence of asymmetries.

Other rare complications associated with botulinum toxin injections include formation of antibodies (less than 1%), which can render treatments ineffective.³⁶ Medications that inhibit neuromuscular signaling such as aminoglycosides, quinidine, anticholinergics, and muscle relaxants, may potentiate botulinum toxin effects.³⁷ AbobotulinumtoxinA is contraindicated in patients with cow's milk protein allergy because bovine protein is a constituent.^{38,39} Although extremely rare, immediate hypersensitivity and allergic reactions may occur, with signs of urticaria, edema, and possibly anaphylaxis. Using standard emergency protocols and medications such as epinephrine and methylprednisolone (Solu-Medrol) is advised when indicated, rather than diphenhydramine (Benadryl) because of its anticholinergic effects.⁴⁰ Case reports of adverse effects due to distant spread from the injection site have been reported with large doses of botulinum toxin (e.g., 300 units in the calves), which include generalized muscle weakness, ptosis, dysphagia, dysarthria, urinary incontinence, respiratory difficulties, and death from respiratory compromise.⁴¹ Distant spread has not been reported with cosmetic use of botulinum toxin for frown lines or other facial indications. There are case reports of botulism with injected botulinum toxin; however, these instances

SORT: KEY RECOMMENDATIONS FOR PRACTICE

<i>Clinical recommendation</i>	<i>Evidence rating</i>	<i>References</i>
Botulinum toxin serotype A is safe and effective for reduction of frown lines.	A	9, 12, 13, 20, 21
Botulinum toxin serotype A is safe and effective for reduction of crow's feet.	A	12, 21, 24, 25
In preparation for botulinum toxin treatment, patients should be advised to discontinue aspirin and any medication or dietary supplements associated with bruising for two weeks before treatment.	C	17, 23

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <http://www.aafp.org/aafpsort>.

involved research-grade botulinum toxin that was not approved or intended for human use.^{42,43}

Financial Considerations and Coding

The current procedural terminology (CPT) designation for botulinum toxin injection of the face is chemodenerivation of muscles innervated by the facial nerve (CPT code: 64612). Cosmetic botulinum toxin treatments are not covered by insurance. Fees for injections range from \$250 to \$550 per treatment area and are based on the number of botulinum toxin units used or on the area treated (i.e., frown lines, crow's feet, or horizontal forehead lines).

Data Sources: A PubMed, Cochrane database, POEMs, and Essential Evidence search was completed in Clinical Queries using the key terms botulinum toxin, safety, efficacy, cosmetic, and frown lines. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Also searched were the FDA website, aesthetic procedure textbooks, and UpToDate. Search dates: February 2, 2013, and April 24, 2014.

The Author

REBECCA SMALL, MD, is an associate clinical professor in the Department of Family and Community Medicine at the University of California–San Francisco School of Medicine and the director of medical aesthetic training at Natividad Medical Center in Salinas, Calif.

Address correspondence to Rebecca Small, MD, 820 Bay Ave., Ste. 246, Capitola, CA 95010 (e-mail: DrSmall@mbla.me). Reprints are not available from the author.

REFERENCES

1. American Society for Aesthetic Plastic Surgery. Cosmetic Surgery National Data Bank statistics 2013. <http://www.surgery.org/media/statistics>. Accessed February 26, 2014.
2. Small R. Aesthetic procedures in office practice. *Am Fam Physician*. 2009;80(11):1231-1237.

3. Carruthers JD, Carruthers A. The use of botulinum toxin type A in the upper face. *Facial Plast Surg Clin North Am*. 2006;14(3):253-260.
4. Cavallini M, Cirillo P, Fundarò SP, et al. Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies. *Dermatol Surg*. 2014;40(5):525-536.
5. Stotland MA, Kowalski JW, Ray BB. Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open-label study. *Plast Reconstr Surg*. 2007;120(5):1386-1393, discussion 1394.
6. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. *Disabil Rehabil*. 2007;29(23):1761-1768.
7. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. *Nature*. 1993;365(6442):160-163.
8. FDA approves Botox Cosmetic to improve the appearance of crow's feet lines [news release]. Silver Springs, Md.: U.S. Food and Drug Administration; September 11, 2013. <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm367662.htm>. Accessed April 18, 2014.
9. Carruthers JA, Lowe NJ, Menter MA, et al.; BOTOX Glabellar Lines I Study Group. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. *J Am Acad Dermatol*. 2002;46(6):840-849.
10. Carruthers A, Carruthers J, Cohen JL. A prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in female subjects with horizontal forehead rhytides. *Dermatol Surg*. 2003;29(5):461-467.
11. Lowe NJ, Lask GP, Yamauchi PS, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. *J Am Acad Dermatol*. 2002;47(6):834-840.
12. Michaels BM, Csank GA, Ryb GE, Eko FN, Rubin A. Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. *Aesthet Surg J*. 2012;32(1):96-102.
13. Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. *Dermatol Surg*. 2010;36(suppl 4):2146-2154.
14. Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)—Part I: upper facial wrinkles. *J Eur Acad Dermatol Venereol*. 2010;24(11):1278-1284.
15. Small R, Hoang D. *A Practical Guide to Botulinum Toxin Procedures*. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2012.
16. Klein AW. Contraindications and complications with the use of botulinum toxin. *Clin Dermatol*. 2004;22(1):66-75.
17. Carruthers J, Fagien S, Matarasso SL; Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. *Plast Reconstr Surg*. 2004;114(6 suppl):1S-22S.
18. Dysport (abobotulinumtoxin A) injection [prescribing information]. Scottsdale, Ariz.: Medicis Aesthetics, Inc.; 2012 <http://pi.medicis.us/dysport.pdf>. Accessed April 18, 2014.
19. Bakshi E, Hartstein ME. Compositional differences among commercially available botulinum toxin type A. *Curr Opin Ophthalmol*. 2011;22(5):407-412.
20. Dessy LA, Fallico N, Mazzocchi M, Scuderì N. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products. *Am J Clin Dermatol*. 2011;12(6):377-388.
21. Kassir R, Kolluru A, Kassir M. Triple-blind, prospective, internally controlled comparative study between abobotulinumtoxinA and onabotulinumtoxinA for the treatment of facial rhytides. *Dermatol Ther (Heidelb)*. 2013;3(2):179-189.
22. Small R. Aesthetic Principles and Consultation. In: Usatine R, Pfenninger J, Stuhlberg D, Small R, eds. *Dermatologic and Cosmetic Procedures in Office Practice*. Philadelphia, Pa.: Elsevier/Saunders; 2012:230-240.
23. Ciocon JO, Ciocon DG, Galindo DJ. Dietary supplements in primary care. Botanicals can affect surgical outcomes and follow-up. *Geriatrics*. 2004;59(9):20-24.
24. Small R. Botulinum Toxin. In: Usatine R, Pfenninger J, Stuhlberg D, Small R, eds. *Dermatologic and Cosmetic Procedures in Office Practice*. Philadelphia, Pa.: Elsevier/Saunders; 2012:248-258.
25. Prager W, Wissmüller E, Kollhorst B, Williams S, Zschocke I. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study. *Dermatol Surg*. 2010;36(suppl 4):2155-2160.
26. Edward M, Zimmerman. Botulinum toxin. In: Pfenninger JL, Fowler GC, eds. *Pfenninger and Fowler's Procedures for Primary Care*. Philadelphia, Pa.: Elsevier/Saunders; 2012:363-372.
27. Beer KR, Boyd C, Patel RK, Bowen B, James SP, Brin MF. Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. *J Drugs Dermatol*. 2011;10(1):39-44.
28. Small R. Botulinum toxin type A for facial rejuvenation. In: Mayeaux E, ed. *The Essential Guide to Primary Care Procedures*. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2009:200-213.
29. Flynn TC. Botulinum toxin: examining duration of effect in facial aesthetic applications. *Am J Clin Dermatol*. 2010;11(3):183-199.
30. Cox SE, Adigun CG. Complications of injectable fillers and neurotoxins. *Dermatol Ther*. 2011;24(6):524-536.
31. Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. *Dermatol Surg*. 2003;29(5):549-556, discussion 556.
32. Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. *Am J Clin Dermatol*. 2005;6(3):141-150.
33. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. *Curr Med Res Opin*. 2004;20(7):981-990.
34. Alam M, Arndt KA, Dover JS. Severe, intractable headache after injection with botulinum A exotoxin: report of 5 cases. *J Am Acad Dermatol*. 2002;46(1):62-65.
35. Toback SL. Medical emergency preparedness in office practice. *Am Fam Physician*. 2007;75(11):1679-1684.
36. Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. *Mov Disord*. 2010;25(13):2211-2218.
37. Botox cosmetic (onabotulinumtoxinA) for injection, for intramuscular use [prescribing information]. Irvine, Calif.: Allergan, Inc.; 2013. http://www.allergan.com/assets/pdf/botox_cosmetic_pi.pdf. Accessed February 26, 2014.
38. U.S. Food and Drug Administration. Information for healthcare professionals: onabotulinumtoxinA (marketed as Botox/Botox Cosmetic), abobotulinumtoxinA (marketed as Dysport) and rimabotulinumtoxinB (marketed as Myobloc). <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm174949.htm>. Accessed February 20 2013.
39. U.S. Food and Drug Administration. Medication guide: Dysport (abobotulinumtoxin A). <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM165110.pdf>. Accessed February 26, 2014.
40. Derksen DJ. Anaphylaxis. In: Pfenninger JL, Fowler GC, eds. *Pfenninger and Fowler's Procedures for Primary Care*. Philadelphia, Pa.: Mosby Elsevier; 2011:1507-1509.
41. Nong LB, He WQ, Xu YH, et al. Severe respiratory failure after injection of botulinum toxin: case report and review of the literature [in Chinese]. *Zhongguo Jie He He Hu Xi Za Zhi*. 2008;31(5):369-371.
42. Souayah N, Karim H, Kamin SS, McArdle J, Marcus S. Severe botulism after focal injection of botulinum toxin. *Neurology*. 2006;67(10):1855-1856.
43. Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. *JAMA*. 2006;296(20):2476-2479.